Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07264634 · ClinicalTrials.gov registry record
A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide)
A clinical trial, sponsored by Ascendis Pharma A/S.
- Recruiting
- Registry status
- 10
- Enrollment target
NCT07264634: Recruiting study, sponsored by Ascendis Pharma A/S.
NCT07264634 is a clinical trial that is actively recruiting participants, run by Ascendis Pharma A/S. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07264634 is actively recruiting participants, sponsored by Ascendis Pharma A/S.
- RECRUITING
- Registry status
- 10 participants
- Enrollment target
Study Summary
This is an observational, opportunistic lactation study to be conducted in lactating female participants who are currently receiving therapeutic doses of YORVIPATH as part of their usual care and who have chosen to breastfeed their infant(s). The potential transfer of palopegteriparatide into breast milk will be assessed.
Interventions
- DRUG Palopegteriparatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2026-03-19 |
| Est. Completion | 2028-01 |
What NCT07264634 shows while recruiting
NCT07264634 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Palopegteriparatide is the first listed.
NCT07264634 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07264634 about?
NCT07264634 is a clinical study titled "A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide)". This is an observational, opportunistic lactation study to be conducted in lactating female participants who are currently receiving therapeutic doses of YORVIPATH as part of their usual care and who have chosen to breastfeed their infant(s). The potential transfer of palopegteriparatide into breast...
What is the current status of trial NCT07264634?
This trial is currently recruiting. The enrollment target is 10 participants. The study started on 2026-03-19. Estimated completion is 2028-01.
What interventions are being tested in trial NCT07264634?
The interventions under investigation include: Palopegteriparatide (DRUG).
Who is sponsoring clinical trial NCT07264634?
This trial is sponsored by Ascendis Pharma A/S, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI